Clinical Trials Logo

Weber-Cockayne Syndrome clinical trials

View clinical trials related to Weber-Cockayne Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT03016715 Recruiting - Clinical trials for Epidermolysis Bullosa Simplex

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

Start date: May 2016
Phase: Phase 2
Study type: Interventional

: Epidermolysis bullosa (EB) simplex is a rare orphan disease caused by a mutation in DNA leading to abnormal dominant keratins in the skin. Patients with EB simplex develop lifelong painful thick soles on their feet, and current standard of care is supportive. This pilot study will target the dominant mutant keratin proteins in the skin to ameliorate the severity of EB simplex. The purpose is to improve the function of EB simplex feet with an application of topical sirolimus, 2%. The investigators plan on inhibiting the mTOR pathway to down regulate the translation of defective keratin proteins and work through anti proliferative pathways.

NCT ID: NCT02960997 Completed - Clinical trials for Epidermolysis Bullosa Simplex

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

Start date: May 2016
Phase: Phase 2
Study type: Interventional

Epidermolysis bullosa (EB) simplex is a rare orphan disease caused by a mutation in DNA leading to abnormal dominant keratins in the skin. Patients with EB simplex develop lifelong painful thick soles on their feet, and current standard of care is supportive. This pilot study will target the dominant mutant keratin proteins in the skin to ameliorate the severity of EB simplex. The purpose is to improve the function of EB simplex feet with an application of topical sirolimus, 2%. The investigators plan on inhibiting the mTOR pathway to down regulate the translation of defective keratin proteins and work through anti proliferative pathways.